The estimated Net Worth of Global Management Lp Logos is at least $7.3 Milión dollars as of 30 October 2020. Global Logos owns over 92,040 units of Dyne Therapeutics stock worth over $7,304,715 and over the last 4 years Global sold DYN stock worth over $0.
Global has made over 2 trades of the Dyne Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Global bought 92,040 units of DYN stock worth $2,341,498 on 30 October 2020.
The largest trade Global's ever made was buying 700,000 units of Dyne Therapeutics stock on 21 September 2020 worth over $13,300,000. On average, Global trades about 396,020 units every 20 days since 2020. As of 30 October 2020 Global still owns at least 224,071 units of Dyne Therapeutics stock.
You can see the complete history of Global Logos stock trades at the bottom of the page.
Global's mailing address filed with the SEC is 1 LETTERMAN DRIVE, STE. D3-700, SAN FRANCISCO, CA, 94129.
Over the last 4 years, insiders at Dyne Therapeutics have traded over $197,573,300 worth of Dyne Therapeutics stock and bought 5,790,447 units worth $92,382,301 . The most active insiders traders include Capital Management, L.P.Kol..., Jason P Rhodes a Dirk Kersten. On average, Dyne Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of $3,566,016. The most recent stock trade was executed by Oxana Beskrovnaya on 11 September 2024, trading 2,161 units of DYN stock currently worth $68,914.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Dyne Therapeutics executives and other stock owners filed with the SEC include: